

**Form 51-102F3**  
**Material Change Report**

**1. Name and Address of Company**

AREV Life Sciences Global Corp. (the "Company")

**2. Date of Material Change**

November 30, 2021

**3. News Release**

A press release was issued on November 30, 2021 and disseminated through Market News and Stockwatch.

**4. Summary of the Material Change**

AREV Acquires Wright & Well Essentials Inc.

**5. Full Description of the Material Change**

VANCOUVER, BC / Nov 30, 2021 / AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) ("AREV" or the "Company") is pleased to announce the Company has closed on the purchase of Wright and Well Essentials Inc. ("Wright & Well") in an all cash deal.

AREV Life Sciences Global Corp. has purchased Wright & Well, a company with an extensive Hemp and Cannabis line of branded products currently being sold in 10 dispensaries in Oregon.

The acquisition of Wright & Well for an all cash deal of twenty thousand (\$20,000) dollars includes but is not limited to:

- A line of full branded products, currently available on the Wright & Well website [www.wrightandwell.com](http://www.wrightandwell.com)
- All finalized branding, packaging and website
- Raw materials currently in inventory

The raw materials, products and packaging valued at \$175,000 as of the last audited financial statements.

This acquisition further expands the depth of the company's core competencies. The products have been formulated using ingredients from Ayurvedic Medicine and Cannabinoids. The company plans to apply its nano-particularization methods to the formulations which will increase the bio-availability and effectiveness of each product and provide a competitive advantage over other cannabinoid products in the market. During the past several months the company has also assembled a Scientific Advisory Board comprised of some of the world's experts in hemp and cannabinoid sciences. The Arev team of scientific advisors contributing to the ongoing review, lab analysis and clinical trials are:

Dr. Robert Melamede has a Ph.D. in Molecular Biology and Biochemistry from the City University of New York. Dr. Melamede is recognized as a leading authority on the therapeutic uses of cannabis, and has authored or co-authored dozens of papers on a wide variety of scientific subjects. He is considered one of the world's leading experts on the human endocannabinoid

system, the complex biological network of neurotransmitters and cell receptors that he calls "the great and powerful wizard behind the curtain." Dr. Bob as he known, is also Program Director Phoenix Tears, (Denver CO).

Dr. Uma Dhanabalan reviews medical records, medications and blood work in family medicine and preventative wellness from her clinic in Massachusetts . As an advocate of holistic treatments; Uplifting Health & Wellness Clinic provides Medicinal Marijuana Card examinations. Dedicating 40-years experience as a Harvard graduate, Dr. Uma Dhanabalan understands the human healing process with Integrative Cannabinology, Functional Endocannabinology and Cannabinoid Medicine.

Dr Jay Noller Dr. Noller is a professor emeritus at Oregon State University (OSU) and is the founding director and lead researcher of OSU's Global Hemp Innovation Center (GHIC). He was the lead in writing the application which was recently awarded a \$10 million grant from the U.S. Department of Agriculture to define economic opportunities for hemp in the western United States. GHIC is the world's most comprehensive research center devoted to the study of hemp, providing the most comprehensive knowledge of hemp innovation to be found anywhere. GHIC is advancing the research of hemp and its market potential across multiple diverse industries and research fields to serve the growing international demand for innovative approaches to food, health, and fiber. Dr. Noller has been Oregon's leader in hemp research and policy since 2014 and has developed research partnerships with over 40 institutions globally devoted to improving hemp genetics and modes of production and processing for fiber, grain essential oils and advances in new classes of hemp varieties. He has directed hemp research and related industrial projects across North America, China, and Europe.

Dr. Richard van Breeman is at the Department of Pharmaceutical Sciences in the Oregon State University College of Pharmacy and in 2021 was named one of the world's most influential analytical scientists by The Analytical Scientist magazine for the second year in a row. He is an expert in biomedical mass spectrometry with a focus on natural products, researches the discovery of drugs from botanicals and investigates the safety and efficacy of botanical dietary supplements. This research integrates the analytical tool of mass spectrometry into all aspects of the drug discovery and development from screening of botanical extracts for the identification of active natural products, to studies of drug metabolism and disposition, and to quantitative analyses of the bioavailability and pharmacokinetics of pharmacologically active compounds. These translational studies extend from basic science to clinical trials.

Dr. Harold Smith is the founder of Cannametrix, LLC., a testing lab with a strategic different approach for establishing new standards for quality control and efficacy of medicinal cannabis. Dr. Smith is a full professor at University of Rochester in the Department of Biochemistry and Biophysics and founder and CEO of OyaGen, Inc. he coordinated a group of Ph.D. scientist in drug discovery for viral diseases. Oyagen recently sold a drug to treat Covid 19.

Mike Withrow, Chief Executive Officer of Arev, commented: "This acquisition enables the company to accelerate its US and Canadian therapeutic wellness market. It leverages Arev's core competency of extraction and provides a turkey branded line". Mr. Withrow continued: "We remain committed to Arev's development on the biomedicinalization of target compounds from botanicals, fungi and select sea animals such as sea cucumber. The results of this work can now be directly applied for the use in Wright & Well Branded products." Visit [www.wrightandwell.com](http://www.wrightandwell.com) to see our new product line and to order products.

The company would also like to announce it has received the Dear Colleague Letter “DCL” titled “The Need to Revise and Amend Ready-To-Use-Therapeutic Food Regulations and Legislation” from its Strategic Advisory Firm in Washington DC. The letter has the support from the necessary House Members to be presented in the 118th CONGRESS 1st Session for the House of Representatives. The company will be providing an update in the coming weeks on the development and activity on the RUTF it continues to work on in collaboration with Voynich Biosciences as previously announced.

6. **Reliance on subsection 7.1(2) or (3) of National Instrument 51 – 102**

Not applicable.

7. **Omitted Information**

Not applicable.

8. **Executive Officer**

Mike Withrow,  
CEO and Director  
Phone: (778) 379-8551

9. **Date of Report**

November 30, 2021